RecruitingPriority 4 · Lower priorityNCT05967949

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Plain-language summary

This study is evaluating chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

Age 18 Years or older
Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

chidamide (DRUG): This subset of patients received chidamide as first-line maintenance therapy.

Drugs / treatments: chidamide
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

NCT05967949

Status: Recruiting | Priority: Lower

Plain-language summary

Who can join

Age 18 Years or older
Newly diagnosed, not yet treated

What's being tested

chidamide (DRUG): This subset of patients received chidamide as first-line maintenance therapy.

Drugs / treatments: chidamide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 200 patients

Primary endpoint: PFS

Ages: 18 Years to —

Start date: 2023-04-01 | Est. completion: 2028-04-01

Locations

0 US sites · 1 total

Contact

wei xu | xuwei10000@hotmail.com | +862568302182

Sponsor: The First Affiliated Hospital with Nanjing Medical University (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05967949

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.